VIB (investor - Others)

See something wrong or missing? Let us know
Offices:Gent

VIB is a Belgium-based life sciences research institute doing research for pharmaceutical, agricultural, and industrial applications.

Average round investment:27.69M USD
Average number per year:1.8
Distribution: 2025 (2)2024 (3)2023 (1)2022 (1)2021 (1) See the entire list
Mostly invests in: Belgium Belgium (11) Biotech (9)
See the entire list

Showing 3 of 14 tracked investments in:


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

VIB mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to VIB

Name Criteria
United States Basis Set Ventures
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, AI (big data)
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United Kingdom Rinkelberg Capital Group
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Fashion
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Germany Cipio Partners
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Agriculture, Manufacturing, Food Industry, Software Services, AI (big data)
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom, Denmark
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Germany Evonik Venture Capital GmbH
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Agriculture, Manufacturing, Software Services, AI (big data)
  • Similar business models: B2B, SAAS
  • Common investees countries: Denmark
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Belgium European Investment Fund
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: Portugal
  • Average number of deals per year: 1.9
  • Active last 12 months: Yes
United States Upfront Ventures
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Food Industry, Software Services, AI (big data)
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Singapore Clay Capital
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Agriculture, Manufacturing, Food Industry, Software Services, AI (big data)
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Luxembourg Alpha Intelligence Capital
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services, AI (big data)
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Germany Christian Edler
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Food Industry, Software Services, AI (big data)
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Netherlands Ingka Investments
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Agriculture, Manufacturing, Food Industry, Software Services, AI (big data)
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom, Denmark
  • Average number of deals per year: 1.9
  • Active last 12 months: Yes
Top